Evidence map›Paper›PMID 35522837›Full record

ArticleBlood cancer discovery2022

Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia.

Tiffany Guess, Chad R Potts, Pawan Bhat, Justin A Cartailler, Austin Brooks, Clinton Holt, Ashwini Yenamandra, Ferrin C Wheeler, Michael R Savona, Jean-Philippe Cartailler and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Blood cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Review
  3. Genes & diseases · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Tiffany GuessDepartment of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center (VUMC), Nashville, Tennessee.ORCID 0000-0002-1659-0434
Chad R PottsDepartment of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center (VUMC), Nashville, Tennessee.ORCID 0000-0003-2319-2474
Pawan BhatProgram in Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Justin A CartaillerDepartment of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center (VUMC), Nashville, Tennessee.
Austin BrooksDepartment of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center (VUMC), Nashville, Tennessee.
Clinton HoltProgram in Chemical and Physical Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Ashwini YenamandraDepartment of Pathology, Microbiology, and Immunology, VUMC, Nashville, Tennessee.
Ferrin C WheelerDepartment of Pathology, Microbiology, and Immunology, VUMC, Nashville, Tennessee.
Michael R SavonaDepartment of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center (VUMC), Nashville, Tennessee.ORCID 0000-0003-3763-5504
Jean-Philippe CartaillerCreative Data Solutions Shared Resource, Center for Stem Cell Biology, Vanderbilt University, Nashville, Tennessee.ORCID 0000-0002-0312-2391
P Brent FerrellDepartment of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center (VUMC), Nashville, Tennessee.
Vanderbilt University · USTennessee Clinical Research Center · USVanderbilt University Medical Center · US

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
MULTIDISCIPLINARY BASIC RESEARCH TRAINING IN CANCERT32CA009592 · NCI · VANDERBILT UNIVERSITY · PI Justin M Balko, Julie A Rhoades (Sterling) · 1987 to 2026
$10.4M
Development of a Phenotype-based Predictive Analytic for Acute Myeloid LeukemiaR01CA262287 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Tomer M Mark, Michael R Savona · 2021 to 2026
$3.2M
EARLY DETECTION OF CLONAL HEMATOPOIESIS AND LEUKEMIA ASSOCIATED MUTATIONS IN WTC EXPOSED FIREFIGHTERS AFTER THE 9/11 ATTACKSU01OH012271 · OH · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI PREZANT, DAVID J, SAVONA, MICHAEL R · 2021 to 2023
$1.5M
Investigating the role of the JAK/STAT3 Pathway in Clonal Proliferation and Immune Dysfunction in Myelodysplastic SyndromeK23HL138291 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI FERRELL, PAUL B · 2017 to 2021
$817k
NCATS NIH HHS UL1 TR002243NCI NIH HHS R01 CA262287NCI NIH HHS T32 CA009592NHLBI NIH HHS K23 HL138291NHLBI NIH HHS L30 HL139435NIOSH CDC HHS U01 OH012271
6 · The paper itself

Abstract

Clonal evolution in myelodysplastic syndrome (MDS) can result in clinical progression and secondary acute myeloid leukemia (sAML). To dissect changes in clonal architecture associated with this progression, we performed single-cell genotyping of paired MDS and sAML samples from 18 patients. Analysis of single-cell genotypes revealed patient-specific clonal evolution and enabled the assessment of single-cell mutational cooccurrence. We discovered that changes in clonal architecture proceed via distinct patterns, classified as static or dynamic, with dynamic clonal architectures having a more proliferative phenotype by blast count fold change. Proteogenomic analysis of a subset of patients confirmed that pathogenic mutations were primarily confined to primitive and mature myeloid cells, though we also identify rare but present mutations in lymphocyte subsets. Single-cell transcriptomic analysis of paired sample sets further identified gene sets and signaling pathways involved in two cases of progression. Together, these data define serial changes in the MDS clonal landscape with clinical and therapeutic implications. SIGNIFICANCE: Precise clonal trajectories in MDS progression are made possible by single-cell genomic sequencing. Here we use this technology to uncover the patterns of clonal architecture and clonal evolution that drive the transformation to secondary AML. We further define the phenotypic and transcriptional changes of disease progression at the single-cell level. See related article by Menssen et al., p. 330 (31). See related commentary by Romine and van Galen, p. 270. This article is highlighted in the In This Issue feature, p. 265.

Indexed as

Leukemia, Myeloid, AcuteMyelodysplastic SyndromesNeoplasms, Second PrimaryClonal EvolutionClone CellsHumansMutation

Identifiers

PMID35522837
PMCPMC9610896
OpenAlexW4229019204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.